Cargando…
An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
SIMPLE SUMMARY: As hypoxia-inducible factor 1 (HIF-1) is recognized as a target for cancer therapy, extensive efforts have been devoted to developing its inhibitors. We provide an overview of the latest information about basic, translational, and clinical research for the development of HIF-1 inhibi...
Autores principales: | Shirai, Yukari, Chow, Christalle C. T., Kambe, Gouki, Suwa, Tatsuya, Kobayashi, Minoru, Takahashi, Itsuki, Harada, Hiroshi, Nam, Jin-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200185/ https://www.ncbi.nlm.nih.gov/pubmed/34200019 http://dx.doi.org/10.3390/cancers13112813 |
Ejemplares similares
-
HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer Cells and Its Therapeutic Significance
por: Nagao, Ayako, et al.
Publicado: (2019) -
Tumor microenvironment and radioresistance
por: Suwa, Tatsuya, et al.
Publicado: (2021) -
SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization
por: Suwa, Tatsuya, et al.
Publicado: (2021) -
Recent Advances in the Application of Cucurbitacins as Anticancer Agents
por: Zieniuk, Bartłomiej, et al.
Publicado: (2023) -
Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview
por: Matiadis, Dimitris, et al.
Publicado: (2020)